Patents by Inventor Michael A. Dyer
Michael A. Dyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170297630Abstract: An integrated fastener for an instrument cluster assembly, where multiple integrated fasteners are used to connect the front cover of the assembly to the back cover. The instrument cluster assembly includes at least one fastener integrated into the back cover, a first recessed portion formed as part of the back cover, and a separation wall formed as part of the back cover in proximity to the first recessed portion. A first mounting aperture is formed as part of the separation wall, and the integrated fastener attached to the back cover and located in the first mounting aperture when the integrated fastener is in a first configuration. The integrated fastener is detached from the back cover and rotated such that the integrated fastener is placed in a second configuration, securing the front cover to the back cover.Type: ApplicationFiled: April 7, 2017Publication date: October 19, 2017Applicant: Continental Automotive Systems, Inc.Inventors: Daniel P. Tollis, Francisco Bolanos Ramirez, Michael E. Carrel, Fernando De Anda Gonzalez, Kevin Michael Dyer, Augusto Guillermo Figueroa Tamayo, Johan Gomez Martinez, Aldo Sainz Hernandez
-
Publication number: 20160297800Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: January 8, 2016Publication date: October 13, 2016Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
-
Patent number: 9266860Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: September 30, 2011Date of Patent: February 23, 2016Assignee: St. Jude Children's Research HospitalInventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
-
Patent number: 9078895Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: GrantFiled: December 5, 2013Date of Patent: July 14, 2015Assignees: St. Jude Children's Research Hospital, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, Leiden University Medical CenterInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
-
Publication number: 20140121218Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: ApplicationFiled: December 5, 2013Publication date: May 1, 2014Applicants: St. Jude Children's Research Hospital, Leiden University Medical Center, Universiteit Gent, Flanders Interuniversity Institute for Biotechnology VIBInventors: Michael A. Dyer, Jean-Christopher Marine, Aart Gerrit Jochemsen
-
Publication number: 20130345237Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: September 30, 2011Publication date: December 26, 2013Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Royappa, Lie Min, Jaeki Min, Anthony Ferreira
-
Patent number: 8614192Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: GrantFiled: July 24, 2007Date of Patent: December 24, 2013Assignees: Leiden University Medical Center, Flanders Interuniversity Institute for Biotechnology, VIB, St. Jude Children's Research HospitalInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
-
Patent number: 8470785Abstract: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.Type: GrantFiled: September 27, 2011Date of Patent: June 25, 2013Assignees: St. Jude Children's Research Hospital, Leiden University Medical Center, VIB VZW and Universiteit GentInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen, R. Kip Guy, Fangyi Zhu
-
Publication number: 20120115880Abstract: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.Type: ApplicationFiled: September 27, 2011Publication date: May 10, 2012Applicant: St. Jude Children's Research HospitalInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen, R. Kip Guy
-
Publication number: 20090298785Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: ApplicationFiled: July 24, 2007Publication date: December 3, 2009Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
-
Publication number: 20080241780Abstract: The present invention generally provides a system for warming an outdoor surface. The system includes a heat exchange unit to provide heated air for use across the surface to melt snow or ice or to warm, evaporate or distribute water. The heat exchange unit is used to recapture the heated air. The present invention also generally provides a method of warming an outdoor surface. The method comprises the steps of providing heated air across the surface to melt snow or ice or to warm, evaporate or distribute water, recapturing the heated air, and redistributing the heated air across the surface.Type: ApplicationFiled: March 28, 2008Publication date: October 2, 2008Inventor: Michael Dyer
-
Patent number: 7023401Abstract: An antenna reflector and an associated latch system are provided. The antenna reflector includes a plurality of reflector portions that are connected in a predetermined configuration to define a continuous surface, such as a parabolic surface. The latches connect the reflector portions. Each latch includes first and second latch members, which define reference surfaces that are structured to contact when the latch is closed. In particular, the reference surfaces are disposed at predetermined and dissimilar distances from connection features of the respective latch members. For example, the first and second reference surfaces of the respective latch members can be disposed at first and second distances from apertures through the respective latch members. The first distance can be greater than the second distance so that, when a fastener is disposed through both apertures, the reference surfaces are urged together and the reflector portions are connected in a predetermined configuration.Type: GrantFiled: July 9, 2004Date of Patent: April 4, 2006Assignee: VertexrsiInventors: Keith Edward Thrash, Michael Dyer, Jeremy Bartell
-
Publication number: 20060007050Abstract: An antenna reflector and an associated latch system are provided. The antenna reflector includes a plurality of reflector portions that are connected in a predetermined configuration to define a continuous surface, such as a parabolic surface. The latches connect the reflector portions. Each latch includes first and second latch members, which define reference surfaces that are structured to contact when the latch is closed. In particular, the reference surfaces are disposed at predetermined and dissimilar distances from connection features of the respective latch members. For example, the first and second reference surfaces of the respective latch members can be disposed at first and second distances from apertures through the respective latch members. The first distance can be greater than the second distance so that, when a fastener is disposed through both apertures, the reference surfaces are urged together and the reflector portions are connected in a predetermined configuration.Type: ApplicationFiled: July 9, 2004Publication date: January 12, 2006Inventors: Keith Thrash, Michael Dyer, Jeremy Bartell
-
Publication number: 20050086708Abstract: Complimentary animal models for retinoblastoma which recapitulate conditions found in the eye of human retinoblastoma patients in an animal are provided. These models are generated by introducing an agent capable of giving rise to a retinoblastoma into the developing eye of an immunologically naive animal. In one model the agent comprises cells which are capable of giving rise to a retinoblastoma. In another model the agent comprises a vector capable of expressing an oncogene which, when expressed in a transfected cell, can give rise to a cell mass that mimics the early stages of retinoblastoma formation. These models can be used to study retinoblastoma and screen for, or characterize, inhibitory agents. These models may also be used to study the influence of genotype or engineered genes or gene deficiencies (knock-outs) on the development of retinoblastoma.Type: ApplicationFiled: October 12, 2004Publication date: April 21, 2005Inventor: Michael Dyer
-
Patent number: 6557852Abstract: Cubic senary (base 6) dice uniquely harness the power of the base 6 number system and generate random numbers from a predetermined set of consecutive numbers, each tending to occur with the same relative frequency. Cubic senary dice have numerical values corresponding to the place values of the base 6 number system, and face values corresponding to the senary notational digits (0, 1, 2, 3, 4, 5). Notational digits on cubic senary dice have two values: an intrinsic value—which is that signified by the isolated symbol itself, and a local value—the value possessed by the numeral by virtue of the power of its die, 60, 61, 62, etc. The magnitude of the senary number cast is a sum of products involving powers of the number 6. A random senary number is obtained by casting the dice and reading the notational digits returned from each die cast, in order, from the highest to the lowest power die. The random senary number is converted to its decimal equivalent with a calculator.Type: GrantFiled: August 20, 2001Date of Patent: May 6, 2003Inventor: Michael Dyer Cuddy